Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados, Christina Charles‐Schoeman, Zoltán Szekanecz, Jon T. Giles, Steven R. Ytterberg, Deepak L. Bhatt, Gary G. Koch, Ivana Vranić, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Carol A. Connell, Arne Yndestad, Jose L. Rivas, Maya H Buch
Abstract
A recent report from the Belimumab Pregnancy Registry (NCT01532310) analysed available data on the consequences of belimumab (BEL) use in pregnant women with systemic lupus erythematosus (SLE). 1 Although limited by multiple confounders and methodological differences, the study did not reveal an on July 21,
Topics & Concepts
MedicineTofacitinibRheumatoid arthritisIncidence (geometry)Adverse effectArthritisInternal medicinePhysical therapyOpticsPhysicsRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchPeripheral Neuropathies and Disorders